HARVARD BIOSCIENCE INC: A Look at Their Latest Annual Report

Considering an investment in Harvard Bioscience (HBIO)? This SEC filing summary breaks down their recent annual report, offering a clear, straightforward overview of the company's operations, financial performance, and future outlook. We aim to provide insights without complex financial jargon, helping retail investors understand what HBIO does and how it performed this past year.

This report covers the fiscal year ended December 31, 2025, with the company filing it on March 5, 2026. HBIO stock trades on The Nasdaq Capital Market under the ticker symbol HBIO.

Business Overview: What Harvard Bioscience Does

Harvard Bioscience (HBIO) develops, manufactures, and markets scientific instruments and laboratory equipment globally. The company primarily serves the life science research community, including universities, pharmaceutical and biotechnology companies, and government research institutions. HBIO's products are essential tools for drug discovery, basic research, and preclinical testing, with a focus on cell and organ physiology, neuroscience, and molecular biology.

Competitive Position: Navigating a Dynamic Market

Harvard Bioscience operates in a highly competitive global market for life science tools and laboratory equipment. Key competitive factors include product innovation, performance, reliability, price, customer service, and brand reputation. HBIO competes with various global and regional manufacturers, some possessing greater financial, technical, and marketing resources.

To differentiate itself, Harvard Bioscience focuses on specialized product offerings, technological advancements, and strong customer relationships within its niche markets.

Investor Status & Reporting: Compliance and Transparency

Harvard Bioscience is classified as a "smaller reporting company" and a "non-accelerated filer." Its public float (the value of shares available to the public) was approximately $18.2 million as of June 30, 2025.

HBIO has consistently filed all required reports with the SEC, demonstrating strong regulatory compliance. Both management and independent auditors have also confirmed the effectiveness of their internal controls over financial reporting. This assurance indicates that the financial data presented is reliable and accurately reflects their business.

As of March 5, 2026, approximately 44.7 million shares of the company's stock were outstanding.

This summary provides a snapshot of Harvard Bioscience's operations, competitive landscape, and compliance. For a complete understanding, always refer to the full SEC filing and conduct your own thorough research before making any investment decisions.